Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 46-year-old woman initially diagnosed with 21-hydroxylase deficiency congenital adrenal hyperplasia was later identified as having 3β-HSD2 deficiency after further investigation, highlighting the need for awareness of rarer CAH forms to prevent delayed diagnosis and insufficient treatment.

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

This study found that neuroactive steroids like DHEA and pregnenolone influence cocaine-induced appetence in mice through their interaction with the ς₁ receptor, suggesting a role in individual vulnerability to addiction.

This review covers the pathophysiology, diagnosis, and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency and reports no new findings.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This study found that allopregnanolone has a bimodal effect on prolactin secretion in sheep, stimulating PRL mRNA expression but inhibiting hormone release under stress and pregnancy conditions.

A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This study found a significant negative correlation between adrenal hormone DHEAS levels and ovarian volume in Greek women with polycystic ovary syndrome, though further clinical research is needed to confirm these results.

This article reviews congenital adrenal hyperplasia, a group of rare genetic disorders affecting steroid synthesis, and highlights the need for specific therapy and ongoing monitoring, but reports no new clinical findings.

In this study, researchers observed that testicular 17β-hydroxysteroid dehydrogenase deficiency in an inbred Arab population in Israel leads to genital ambiguity at birth and progressive virilization after puberty.

This study found that higher levels of dihydrotestosterone in the parietal region of the scalp may correlate with the clinical presentation of androgenetic alopecia.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This case report emphasizes the importance of recognizing non-classic congenital adrenal hyperplasia as a cause of hyperandrogenism and the need for genetic counseling given potential familial implications.

This study found that women with polycystic ovary syndrome had significantly higher serum and intrafollicular levels of anti-Müllerian hormone compared to normovulatory women, indicating a potential marker for ovarian hyperstimulation syndrome risk.

This study found that medroxyprogesterone acetate and ethinyl estradiol with drospirenone were the most frequently prescribed medications for PCOS, with some patients experiencing drug changes or discontinuation due to side effects or therapeutic failure.

This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.

This article reviews the use of several medications for ovulation induction in polycystic ovary syndrome and hirsutism treatment, noting these uses are not FDA-approved; no new clinical results are provided.

In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.

This review discusses the challenges in optimizing glucocorticoid treatment for classic 21-hydroxylase deficiency, emphasizing individualized care and the need for comprehensive management, but presents no new findings.

In this study of women with hirsutism or androgenic alopecia, diverse underlying endocrine disorders including polycystic ovaries and various enzyme deficiencies were detected, often associated with elevated testosterone levels.

In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.

This review covers the pathophysiology, diagnosis, and treatment of nonclassic congenital adrenal hyperplasia due to P450c21, but it reports no new clinical results.

This review discusses idiopathic hirsutism, potential underlying mechanisms, and various therapeutic approaches without providing new clinical results, and emphasizes the need for further research on well-defined patient groups.

This study describes a new method using high-resolution mass spectrometry for analyzing multiple steroids in human scalp hair, with newborn hair showing the highest steroid concentrations among examined age groups.

This study found that women with polycystic ovarian syndrome at a gynecology clinic in Nnewi exhibited significant oxidative stress and hormonal imbalances compared to controls.

This study observes the expression of mRNA for androgen receptor, 5α‐reductase, and 17β‐hydroxysteroid dehydrogenase in human dermal papilla cells.